Eli Lilly, Novo Are Weight-Loss Winners. Rivals Won't Be an Issue for Years: Analyst. -- Barrons.com
Deutsche Bank Raises Intuitive Surgical Price Target to $445 From $390, Maintains Hold Rating
Intuitive Surgical (ISRG) Receives a Buy From BTIG
BTIG Maintains Intuitive Surgical(ISRG.US) With Buy Rating, Maintains Target Price $469
Barclays Maintains Intuitive Surgical(ISRG.US) With Buy Rating, Maintains Target Price $490
BMO Capital raised AbbVie's target price to $214.
Analysts' Top Healthcare Picks: 4D Molecular Therapeutics (FDMT), Intuitive Surgical (ISRG)
Outperform Rating Reaffirmed for Intuitive Surgical on Strong Q2 2024 Performance and Da Vinci 5 Launch Success
AbbVie Analyst Ratings
BMO Capital Maintains Outperform on AbbVie, Raises Price Target to $214
Jefferies Adjusts Price Target on Amgen to $380 From $375
HSBC Raises Price Target on Eli Lilly to $1,100 From $880, Maintains Buy Rating
Piper Sandler Maintains Overweight on Intuitive Surgical, Raises Price Target to $495
Piper Sandler Remains a Buy on Intuitive Surgical (ISRG)
JPMorgan Adjusts Price Target on Intuitive Surgical to $495 From $475, Maintains Overweight Rating
Analysts' Top Healthcare Picks: Intuitive Surgical (ISRG), Nuvation Bio (NUVB)
Strong Performance and Growth Prospects Underpin Buy Rating for Intuitive Surgical
Barclays Maintains Overweight on Intuitive Surgical, Raises Price Target to $490
Intuitive Surgical Analyst Ratings
Barclays Remains a Buy on Intuitive Surgical (ISRG)